This would be comparable to the approach of blocking acetylcholinesterase (AChE) with selective inhibitors (to increase ACh levels) to counteract the loss of cholinergic neurons in Alzheimer’s disease, or selectively activating dopamine receptors with agonists to counter the loss of dopaminergic neurons in Parkinson’s disease. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.